Epirus Biopharmaceuticals Stock Retained Earnings
| EPRSQDelisted Stock | USD 0.0001 0.00 0.00% |
EPIRUS Biopharmaceuticals fundamentals help investors to digest information that contributes to EPIRUS Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of EPIRUS Pink Sheet. The fundamental analysis module provides a way to measure EPIRUS Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to EPIRUS Biopharmaceutica pink sheet.
EPIRUS |
EPIRUS Biopharmaceuticals Company Retained Earnings Analysis
EPIRUS Biopharmaceutica's Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current EPIRUS Biopharmaceutica Retained Earnings | (155.03 M) |
Most of EPIRUS Biopharmaceutica's fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, EPIRUS Biopharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
CompetitionBased on the latest financial disclosure, EPIRUS Biopharmaceuticals has a Retained Earnings of (155.03 Million). This is 116.65% lower than that of the Biotechnology sector and 260.0% lower than that of the Health Care industry. The retained earnings for all United States stocks is 101.66% higher than that of the company.
EPIRUS Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses EPIRUS Biopharmaceutica's direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of EPIRUS Biopharmaceutica could also be used in its relative valuation, which is a method of valuing EPIRUS Biopharmaceutica by comparing valuation metrics of similar companies.EPIRUS Biopharmaceutica is currently under evaluation in retained earnings category among its peers.
EPIRUS Fundamentals
| Return On Equity | -1.22 | |||
| Return On Asset | -0.45 | |||
| Operating Margin | (37.45) % | |||
| Current Valuation | (6 M) | |||
| Shares Outstanding | 26.18 M | |||
| Number Of Shares Shorted | 252.54 K | |||
| Price To Earning | (0.01) X | |||
| Price To Book | 0 X | |||
| Price To Sales | 0.0001 X | |||
| Revenue | 701 K | |||
| Gross Profit | 576 K | |||
| EBITDA | (54.6 M) | |||
| Net Income | (52.19 M) | |||
| Cash And Equivalents | 20.86 M | |||
| Cash Per Share | 0.80 X | |||
| Total Debt | 14.85 M | |||
| Debt To Equity | 0.57 % | |||
| Current Ratio | 0.79 X | |||
| Book Value Per Share | 1.00 X | |||
| Cash Flow From Operations | (46.58 M) | |||
| Short Ratio | 0.07 X | |||
| Earnings Per Share | (2.52) X | |||
| Target Price | 2.0 | |||
| Number Of Employees | 73 | |||
| Beta | 4.28 | |||
| Market Capitalization | 157 | |||
| Total Asset | 72.26 M | |||
| Retained Earnings | (155.03 M) | |||
| Working Capital | (6.93 M) | |||
| Current Asset | 25.69 M | |||
| Current Liabilities | 32.63 M | |||
| Z Score | -2.8 | |||
| Net Asset | 72.26 M |
About EPIRUS Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze EPIRUS Biopharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of EPIRUS Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of EPIRUS Biopharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with EPIRUS Biopharmaceutica
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if EPIRUS Biopharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in EPIRUS Biopharmaceutica will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to EPIRUS Biopharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace EPIRUS Biopharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back EPIRUS Biopharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling EPIRUS Biopharmaceuticals to buy it.
The correlation of EPIRUS Biopharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as EPIRUS Biopharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if EPIRUS Biopharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for EPIRUS Biopharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Other Consideration for investing in EPIRUS Pink Sheet
If you are still planning to invest in EPIRUS Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EPIRUS Biopharmaceutica's history and understand the potential risks before investing.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| CEOs Directory Screen CEOs from public companies around the world |